Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1) |
| |
| Authors: | Birgit C Schultes Richard P Baum Andreas Niesen Antoine A Noujaim R Madiyalakan |
| |
| Institution: | AltaRex Corp., 300 Campus Tower, 8625 112 St. Edmonton, Alberta, T6G 1K8, Canada Fax +1 403 436 0068, CA
Nuklearmedizin, Universit?tsklinikum, Frankfurt, Germany, DE
|
| |
| Abstract: | Intravenous injection of the murine monoclonal anti-CA125 antibody B43.13 (Ovarex: Ab1) into ovarian cancer patients led to the induction of an idiotypic network. Of the 75 patients who received one to ten injections
of a 2-mg dose of the antibody, 48 developed anti-(mAb B43.13) antibodies (Ab2); 18 of these patients also had elevated levels of anti-anti-(mAb B43.13)] antibodies (Ab3; = anti-CA125 antibodies) compared to pre-injection values. Characterization of these antibodies revealed that the binding
to CA125 could be inhibited by mAb B43.13 in most samples. Human anti-CA125 antibodies or Ab3 purified from patient serum samples specifically recognized human ovarian tumor cells and tissues expressing CA125. In addition,
these anti-CA125 antibodies were able to conduct Fc-mediated tumor cell killing (antibody-dependent cell-mediated cytotoxicity). This raises the possibility of using an Ab1 for anti-idiotype induction immunotherapy of cancer.
Received: 14 October 1997 / Accepted: 9 January 1998 |
| |
| Keywords: | Anti-CA125 antibody mAb B43 13 Immunotherapy Anti-idiotypic network ADCC Immune histochemistry |
| 本文献已被 SpringerLink 等数据库收录！ |
|
